Zymeworks ( (ZYME) ) just unveiled an update.
Zymeworks reported its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its product pipeline, including the initiation of first-in-human studies for ZW191 and ZW171. The company also announced the FDA’s accelerated approval of Ziihera® for HER2-positive biliary tract cancer, marking a major milestone for its partnered product. With a strong cash position and anticipated regulatory milestone payments, Zymeworks projects a cash runway into the second half of 2027, supporting its continued development efforts and strategic partnerships.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing a diverse pipeline of novel, multifunctional biotherapeutics aimed at improving the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease.
YTD Price Performance: -13.73%
Average Trading Volume: 459,749
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $885.5M
For an in-depth examination of ZYME stock, go to TipRanks’ Stock Analysis page.